サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1769672

神経性過活動膀胱の世界市場レポート2025年

Neurogenic Detrusor Overactivity Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
神経性過活動膀胱の世界市場レポート2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経性過活動膀胱市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.7％で24億5,000万米ドルに成長します。予測期間の成長促進要因としては、高齢化、脊髄損傷症例の増加、ヘルスケア支出の増加、低侵襲治療の進歩、患者の意識と教育の向上などが挙げられます。この期間の主な動向としては、幹細胞治療の技術進歩、薬物送達システムの革新、神経調節装置の改良、個別化医療研究の進歩、低侵襲治療法の開発などが挙げられます。

神経疾患の罹患率の上昇は、今後数年間の神経性過活動膀胱（NDO）市場の成長を牽引すると予想されます。神経疾患は、脳、脊髄、神経に影響を及ぼし、運動、感覚、認知、その他の身体機能に問題をもたらす病状です。人々が長生きするにつれて、加齢に関連した脳の変性が起こる可能性が高くなり、これらの疾患の有病率が高まる一因となっています。NDOは、脊髄損傷、多発性硬化症、パーキンソン病などの神経疾患と関連することが多い膀胱機能障害の一種です。これらの疾患は、脳と膀胱間の正常な神経伝達を妨げ、不随意な膀胱収縮を引き起こします。例えば、2024年4月、米国神経学会（AAN）が発表した研究によると、2050年までに世界全体で推定49億件の脳障害が発生し、2021年の約40億件から22％増加するといいます。その結果、神経疾患の増加がNDO市場の拡大に寄与しています。

神経性過活動膀胱の治療に携わる主要企業は、低コストで効果的な膀胱制御ソリューションを提供するため、β3アドレナリン受容体作動薬などの先進的なジェネリック医薬品の開発を重視しています。ミラベグロンなどのこれらの薬剤は、膀胱の起立筋を弛緩させ、それによって膀胱容量を高め、切迫感や失禁などの症状を軽減します。例えば、2024年4月、インドの製薬会社であるLupin Ltd.は、米国食品医薬品局（USFDA）から、Myrbetriqのジェネリック医薬品であるミラベグロンを米国で発売する承認を取得しました。ミラベグロンは1日1回の経口治療薬として、過活動膀胱（OAB）および小児患者の神経性過活動膀胱管理に便利で効率的な選択肢を提供します。今回の承認は、主要な治療分野において高品質で手頃な価格のジェネリック医薬品を提供するというルピンのコミットメントを強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の神経性過活動膀胱：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の神経性過活動膀胱市場：成長率分析
  • 世界の神経性過活動膀胱市場の実績：規模と成長, 2019-2024
  • 世界の神経性過活動膀胱市場の予測：規模と成長, 2024-2029, 2034F
  • 世界の神経性過活動膀胱：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の神経性過活動膀胱市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 非外科的治療
  • 外科的治療
  • フォローアップ治療
  • 世界の神経性過活動膀胱市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 成人用
  • 子供
  • 世界の神経性過活動膀胱市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 泌尿器科クリニック
  • リハビリテーションセンター
  • 個人診療所
  • 長期ケア施設
  • 世界の神経性過活動膀胱市場、非外科的治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 抗ムスカリン薬
  • β3アドレナリン作動薬
  • 行動療法
  • 神経調節
  • 清潔間欠カテーテル法
  • 膀胱内療法
  • 世界の神経性過活動膀胱市場、外科的治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ボツリヌス毒素注射
  • 膀胱増大術
  • 尿路変更
  • 外括約筋切開術
  • 人工尿道括約筋移植
  • 世界の神経性過活動膀胱市場、フォローアップ治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 尿流動態評価
  • 超音波モニタリング
  • 臨床検査
  • 継続的なカテーテル挿入
  • ボツリヌス毒素の繰り返し注射
  • 患者と介護者へのトレーニング
  • 生活の質の評価

第7章 地域別・国別分析

  • 世界の神経性過活動膀胱市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の神経性過活動膀胱市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経性過活動膀胱市場：競合情勢
  • 神経性過活動膀胱市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S. A. Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Intas Pharmaceuticals Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries
  • Apotex Inc.
  • Viatris Inc.
  • Sumitomo Pharma America Inc.
  • Galderma
  • Ipsen
  • Coloplast A/S
  • Aurobindo Pharma Limited
  • Hisamitsu Pharmaceutical Co. Inc.
  • Kaken Pharmaceutical Co. Ltd.
  • Hugel Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 神経性過活動膀胱市場2029：新たな機会を提供する国
  • 神経性過活動膀胱市場2029：新たな機会を提供するセグメント
  • 神経性過活動膀胱市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35987

Neurogenic detrusor overactivity (NDO) is a bladder dysfunction that results from neurological conditions interfering with normal nerve signals between the brain, spinal cord, and the bladder's detrusor muscle. This disruption causes increased or involuntary contractions of the detrusor muscle, leading to symptoms such as urinary urgency, frequent urination, urge incontinence, and occasionally incomplete bladder emptying.

The primary treatment options for neurogenic detrusor overactivity (NDO) include non-surgical treatments, surgical interventions, and follow-up care. Non-surgical treatments involve medical management or therapies that address the condition without requiring invasive surgical procedures. These treatments are utilized across different patient groups, including both adults and children, and are delivered in various settings such as hospitals, urology clinics, rehabilitation centers, private practices, and long-term care facilities.

The neurogenic detrusor overactivity market research report is one of a series of new reports from The Business Research Company that provides neurogenic detrusor overactivity market statistics, including the neurogenic detrusor overactivity industry global market size, regional shares, competitors with the neurogenic detrusor overactivity market share, detailed neurogenic detrusor overactivity market segments, market trends, and opportunities, and any further data you may need to thrive in the neurogenic detrusor overactivity industry. These neurogenic detrusor overactivity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurogenic detrusor overactivity market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The historic growth is attributed to a rise in neurological disorders, increased awareness among healthcare providers, broader adoption of pharmaceutical treatments, development of hospital and clinic facilities, and higher diagnosis rates.

The neurogenic detrusor overactivity market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Growth drivers for the forecast period include the aging population, rising cases of spinal cord injuries, increased healthcare spending, advancements in minimally invasive therapies, and enhanced patient awareness and education. Key trends during this period include technological progress in stem cell therapies, innovation in drug delivery systems, improvements in neuromodulation devices, advances in personalized medicine research, and the development of less invasive treatment procedures.

The rising incidence of neurological disorders is expected to drive the growth of the neurogenic detrusor overactivity (NDO) market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, or nerves, resulting in issues with movement, sensation, cognition, or other bodily functions. As people live longer, the likelihood of age-related brain degeneration increases, contributing to the growing prevalence of these conditions. NDO is a form of bladder dysfunction often linked to neurological disorders such as spinal cord injury, multiple sclerosis, and Parkinson's disease. These conditions interfere with normal nerve communication between the brain and bladder, leading to involuntary bladder contractions. For example, in April 2024, a study published by the American Academy of Neurology (AAN) indicated that there will be an estimated 4.9 billion cases of brain disorders globally by 2050, marking a 22% increase from around 4 billion cases in 2021. Consequently, the increasing number of neurological disorders is contributing to the expansion of the NDO market.

Major companies involved in the treatment of neurogenic detrusor overactivity are emphasizing the development of advanced generic therapies, such as beta-3 adrenergic receptor agonists, to provide effective bladder control solutions at lower costs. These drugs, such as mirabegron, help relax the detrusor muscle in the bladder, thereby enhancing bladder capacity and reducing symptoms like urgency and incontinence. For instance, in April 2024, Lupin Ltd., an Indian pharmaceutical company, received approval from the U.S. Food and Drug Administration (USFDA) to launch Mirabegron, a generic version of Myrbetriq, in the United States. As a once-daily oral treatment, Mirabegron provides a convenient and efficient option for managing overactive bladder (OAB) and neurogenic detrusor overactivity in pediatric patients. This approval underscores Lupin's commitment to offering high-quality and affordable generic medications in key therapeutic areas.

In November 2024, Boston Scientific Corporation, a U.S.-based medical device company, acquired Axonics, Inc. to strengthen its portfolio in neuromodulation and urology. This acquisition aims to enhance Boston Scientific's capabilities in treating overactive bladder and other urinary and bowel dysfunctions by incorporating Axonics' innovative sacral neuromodulation technologies. The integration of Axonics' solutions will allow Boston Scientific to offer more comprehensive care options for pelvic health conditions. Axonics, Inc. is a U.S.-based medical technology firm that specializes in sacral neuromodulation systems designed to improve bladder control.

Major players in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., and Hugel Inc.

North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in neurogenic detrusor overactivity report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurogenic detrusor overactivity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenic detrusor overactivity market includes revenues earned by entities by providing services such as medication management, behavioral and lifestyle interventions, physiotherapy, absorbent products and skin care, and catheterization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenic Detrusor Overactivity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenic detrusor overactivity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurogenic detrusor overactivity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurogenic detrusor overactivity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Types: Non-Surgical Treatment; Surgical Treatment; Follow-Up Treatment
  • 2) By Application: Adult; Child
  • 3) By End-User: Hospitals; Urology Clinics; Rehabilitation Centers; Private Practices; Long-Term Care Facilities
  • Subsegments:
  • 1) By Non-Surgical Treatment: Antimuscarinic Drugs; Beta-3 Adrenergic Agonists; Behavioral Therapy; Neuromodulation; Clean Intermittent Catheterization; Intravesical Therapies
  • 2) By Surgical Treatment: Botulinum Toxin Injection; Augmentation Cystoplasty; Urinary Diversion; External Sphincterotomy; Artificial Urinary Sphincter Implantation
  • 3) By Follow-Up Treatment: Urodynamic Evaluation; Ultrasound Monitoring; Laboratory Tests; Ongoing Catheterization; Repeat Botulinum Toxin Injections; Patient and Caregiver Training; Quality of Life Assessment
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Sanofi S. A.; Medtronic plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurogenic Detrusor Overactivity Market Characteristics

3. Neurogenic Detrusor Overactivity Market Trends And Strategies

4. Neurogenic Detrusor Overactivity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurogenic Detrusor Overactivity Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neurogenic Detrusor Overactivity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neurogenic Detrusor Overactivity Market Growth Rate Analysis
  • 5.4. Global Neurogenic Detrusor Overactivity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neurogenic Detrusor Overactivity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neurogenic Detrusor Overactivity Total Addressable Market (TAM)

6. Neurogenic Detrusor Overactivity Market Segmentation

  • 6.1. Global Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Surgical Treatment
  • Surgical Treatment
  • Follow-Up Treatment
  • 6.2. Global Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Adult
  • Child
  • 6.3. Global Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Urology Clinics
  • Rehabilitation Centers
  • Private Practices
  • Long-Term Care Facilities
  • 6.4. Global Neurogenic Detrusor Overactivity Market, Sub-Segmentation Of Non-Surgical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antimuscarinic Drugs
  • Beta-3 Adrenergic Agonists
  • Behavioral Therapy
  • Neuromodulation
  • Clean Intermittent Catheterization
  • Intravesical Therapies
  • 6.5. Global Neurogenic Detrusor Overactivity Market, Sub-Segmentation Of Surgical Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Botulinum Toxin Injection
  • Augmentation Cystoplasty
  • Urinary Diversion
  • External Sphincterotomy
  • Artificial Urinary Sphincter Implantation
  • 6.6. Global Neurogenic Detrusor Overactivity Market, Sub-Segmentation Of Follow-Up Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Urodynamic Evaluation
  • Ultrasound Monitoring
  • Laboratory Tests
  • Ongoing Catheterization
  • Repeat Botulinum Toxin Injections
  • Patient and Caregiver Training
  • Quality of Life Assessment

7. Neurogenic Detrusor Overactivity Market Regional And Country Analysis

  • 7.1. Global Neurogenic Detrusor Overactivity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neurogenic Detrusor Overactivity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurogenic Detrusor Overactivity Market

  • 8.1. Asia-Pacific Neurogenic Detrusor Overactivity Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurogenic Detrusor Overactivity Market

  • 9.1. China Neurogenic Detrusor Overactivity Market Overview
  • 9.2. China Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurogenic Detrusor Overactivity Market

  • 10.1. India Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurogenic Detrusor Overactivity Market

  • 11.1. Japan Neurogenic Detrusor Overactivity Market Overview
  • 11.2. Japan Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurogenic Detrusor Overactivity Market

  • 12.1. Australia Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurogenic Detrusor Overactivity Market

  • 13.1. Indonesia Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurogenic Detrusor Overactivity Market

  • 14.1. South Korea Neurogenic Detrusor Overactivity Market Overview
  • 14.2. South Korea Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurogenic Detrusor Overactivity Market

  • 15.1. Western Europe Neurogenic Detrusor Overactivity Market Overview
  • 15.2. Western Europe Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurogenic Detrusor Overactivity Market

  • 16.1. UK Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurogenic Detrusor Overactivity Market

  • 17.1. Germany Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurogenic Detrusor Overactivity Market

  • 18.1. France Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurogenic Detrusor Overactivity Market

  • 19.1. Italy Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurogenic Detrusor Overactivity Market

  • 20.1. Spain Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurogenic Detrusor Overactivity Market

  • 21.1. Eastern Europe Neurogenic Detrusor Overactivity Market Overview
  • 21.2. Eastern Europe Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurogenic Detrusor Overactivity Market

  • 22.1. Russia Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurogenic Detrusor Overactivity Market

  • 23.1. North America Neurogenic Detrusor Overactivity Market Overview
  • 23.2. North America Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurogenic Detrusor Overactivity Market

  • 24.1. USA Neurogenic Detrusor Overactivity Market Overview
  • 24.2. USA Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurogenic Detrusor Overactivity Market

  • 25.1. Canada Neurogenic Detrusor Overactivity Market Overview
  • 25.2. Canada Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurogenic Detrusor Overactivity Market

  • 26.1. South America Neurogenic Detrusor Overactivity Market Overview
  • 26.2. South America Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurogenic Detrusor Overactivity Market

  • 27.1. Brazil Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurogenic Detrusor Overactivity Market

  • 28.1. Middle East Neurogenic Detrusor Overactivity Market Overview
  • 28.2. Middle East Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurogenic Detrusor Overactivity Market

  • 29.1. Africa Neurogenic Detrusor Overactivity Market Overview
  • 29.2. Africa Neurogenic Detrusor Overactivity Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neurogenic Detrusor Overactivity Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neurogenic Detrusor Overactivity Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurogenic Detrusor Overactivity Market Competitive Landscape And Company Profiles

  • 30.1. Neurogenic Detrusor Overactivity Market Competitive Landscape
  • 30.2. Neurogenic Detrusor Overactivity Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S. A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis

31. Neurogenic Detrusor Overactivity Market Other Major And Innovative Companies

  • 31.1. Teva Pharmaceutical Industries Ltd.
  • 31.2. Astellas Pharma Inc.
  • 31.3. Intas Pharmaceuticals Ltd.
  • 31.4. Macleods Pharmaceuticals Ltd.
  • 31.5. Sun Pharmaceutical Industries
  • 31.6. Apotex Inc.
  • 31.7. Viatris Inc.
  • 31.8. Sumitomo Pharma America Inc.
  • 31.9. Galderma
  • 31.10. Ipsen
  • 31.11. Coloplast A/S
  • 31.12. Aurobindo Pharma Limited
  • 31.13. Hisamitsu Pharmaceutical Co. Inc.
  • 31.14. Kaken Pharmaceutical Co. Ltd.
  • 31.15. Hugel Inc.

32. Global Neurogenic Detrusor Overactivity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurogenic Detrusor Overactivity Market

34. Recent Developments In The Neurogenic Detrusor Overactivity Market

35. Neurogenic Detrusor Overactivity Market High Potential Countries, Segments and Strategies

  • 35.1 Neurogenic Detrusor Overactivity Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neurogenic Detrusor Overactivity Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neurogenic Detrusor Overactivity Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer